Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
Venture Capital Firms Attend EuroMedtech in Force
Seeking investments, high investor turn-out bodes well for medtech start-ups and emerging companies
CARLSBAD, Calif. & DUESSELDORF, Germany Already over 25 venture capitalists (VCs) are registered to attend the inaugural EuroMedtech™ 2009 partnering conference at the Maritim Hotel in Duesseldorf, Germany on June 3–4. Powered by partneringONE™, the industry’s most advanced partnering system, EuroMedtech facilitates one-to-one meetings between emerging innovator firms, large multi-disciplinary healthcare and biomedical companies and investment firms.
Held in one of the largest life science clusters in Europe, EuroMedtech 2009 will play host to leading European VC firms such as Abingworth, Edmond de Rothschild Investment Partners, Earlybird Venture Capital, Sofinnova, NIBC Capital Partners I B.V., Gilde Healthcare Partners and High-Tech Gründerfonds. Attracting a critical mass of emerging innovator medtech companies, these VCs view EuroMedtech as an exceptional opportunity to discover, meet with and evaluate companies with technologies that address unmet medical needs or provide a cost effective alternative to current treatments.
Describing his views on medtech investing and partnering at EuroMedtech 2009, Olivier Litzka, partner with venture firm Edmond de Rothschild Investment Partners, said: “I believe that EuroMedtech can become a premium event for medical technology in the way that EBD Group’s BIO-Europe conference has proven to be important for biotechnology. There is a need for this event because medical technology has been underserved for real partnering. The expertise is here in Europe and clearly there are interested investors. Combining that with the champion partnering capabilities we have seen with EBD Group is fantastic and really creates a chance to move things forward.”
Elaborating on her views of medtech investing, Dr. Caroline Fichtner, Investment Manager for High-Tech Gründerfonds Management, commented: “A third of our portfolio is in life sciences and out of this at least one third is for medical technologies. It is a very vital segment for investment for us and very attractive in terms of the shorter approval timelines for e.g. devices and the funding necessary to reach milestones. Our investment is limited to EUR 500,000 in the seed financing so it is easier to get to key milestones in the medtech area with that kind of funding.”
“We see a lot of attractive opportunities for medical technology among German companies because this sector is especially strong here with several large multinational companies and a traditionally heavy focus in research and development,” she added.
EuroMedtech 2009 Venture Academy
To help ensure that presentations have the maximum impact at the EuroMedtech conference, innovative start-up companies, spin-off enterprises and technology transfer departments will receive intensive coaching and feedback from industry insiders and investors at a Venture Academy, being held on June 2nd at the Life Science Center in Dusseldorf.
Organized by EBD Group in collaboration with the German State of North Rhein-Westphalia and the City of Duesseldorf, the Venture Academy is a half-day program that aims to provide a taste of the real world of doing business for these young companies.
Invited panelists, who will also offer pointers and helpful suggestions for presentations, include Dr. Hubertus Rosery from Assessment in Medicine (AiM), Dr. Klaus Nestler from CFP BioConnect AG and Dr. Christine Fitchner from High-Tech Gründerfonds Management GmbH. They will be accompanied by Reinhard Merz of TCG, Christian Schneider, from Vesalius BioCapital and Martin Krauss with FGK Clinical Research.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe and BIO-Europe Spring®, the world’s largest stand-alone life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, EBD Group’s North American partnering event
- EuroMedtech™, EBD Group’s new partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China
EBD Group’s sophisticated web-based partnering service, partneringONE™, is used as the partnering engine at numerous third-party events around the world. Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Source: EBD Group